StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $18.66 | $18.27 | -2.09% | 0.1M |
| 05-12 | $18.32 | $19.73 | +7.70% | 0.1M |
| 05-13 | $19.47 | $19.53 | +0.31% | 0.1M |
| 05-14 | $19.72 | $19.50 | -1.12% | 0.1M |
| 05-15 | $19.09 | $19.55 | +2.41% | 0.1M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for AKTS.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for AKTS.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
| Metric | Q1 2026 2026-03-31 | Q1 2025 2025-03-31 |
|---|---|---|
Revenue | $3.23M | $1.45M |
Operating Income | $-22.71M | $-18.14M |
Net Income | $-18.32M | $-14.98M |
EPS (Diluted) | $-0.38 | $-18.60 |
Total Assets | $576.80M | Not available |
Total Liabilities | $70.69M | Not available |
Cash & Equivalents | $371.63M | $58.25M |
Free Cash Flow OCF − CapEx | $-26.10M | $-19.38M |
Shares Outstanding | 53.40M | 805.82K |